Riskpilot← Back to searchSign inGet full accessMIDTUN APOTEK AS
ASActiveOrg 923990631Sandbrekkevegen 96, 5225 NesttunRetail sale of pharmaceutical products · NACE 4773Est. 20208 employees
Revenue 2024
NOK 29,3M
+17% vs 2023
EBITDA margin
5.7%
+29% vs 2023
Equity ratio
21.9%
Financial strength
Net profit 2024
NOK 1,3M
+33% vs 2023
| Revenue | NOK 29,3M | +17% |
| EBITDA | NOK 1,7M | +29% |
| Net profit | NOK 1,3M | +33% |
| Total assets | NOK 11M | +47% |
| Equity | NOK 2,4M | +110% |
| Employees | 8 | — |
Legal name
MIDTUN APOTEK AS
Org number
923990631
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
14. januar 2020
Share capital
NOK 30 000
Employees
8 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap. Styrets leder og ett styremedlem i fellesskap.
Company purpose
Apotek.
Address
Sandbrekkevegen 96, 5225 Nesttun
Phone
+4755102218
Email
apotek1.midtun@apotek1.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3 691 | 16 585 | 19 362 | 25 047 | 29 315 |
| Staff expenses | −539 | −2 163 | −3 289 | −3 711 | −3 848 |
| EBITDA | 77 | 1 401 | 224 | 1 294 | 1 666 |
| Depreciation & amort. | −22 | −66 | −66 | −66 | −66 |
| EBIT | 55 | 1 335 | 158 | 1 228 | 1 600 |
| Net financials | −10 | −9 | −1 | −2 | 13 |
| Profit before tax | 45 | 1 327 | 157 | 1 226 | 1 613 |
| Tax | 10 | 293 | 51 | 275 | 351 |
| Net profit | 35 | 1 033 | 106 | 951 | 1 262 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3 920 | 4 346 | 4 938 | 7 477 | 11 007 |
| Equity | 53 | 1 086 | 192 | 1 143 | 2 405 |
| Long-term debt | 462 | 36 | 40 | 32 | 35 |
| Short-term debt | 3 405 | 3 224 | 4 707 | 6 301 | 8 568 |
| Total debt | 3 867 | 3 260 | 4 747 | 6 334 | 8 602 |
EBITDA margin
5.7%
This company
15.8%
Market median
-64% vs market
20202024
Equity ratio
21.9%
This company
38.2%
Market median
-43% vs market
20202024
Return on equity
52.5%
This company
18.4%
Market median
+185% vs market
20202024
Net profit margin
4.3%
This company
8.1%
Market median
-47% vs market
20202024
Asset turnover
2.66×
This company
1.12×
Market median
+138% vs market
20202024
Debt / equity
3.58×
This company
0.62×
Market median
-477% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AG Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2025 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Bergensapotekene As | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Bergensapotekene As
MIDTUN APOTEK AS Board members of MIDTUN APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Alessio Guerra | Chief Executive Officer | 0 companies |
| Børge Moholt | Chairman | 0 companies |
| Christina Wang Oftedal | Chairman | 0 companies |
| Øystein Askim | Board of Directors | 0 companies |